[3] [4] The cardiovascular safety profile of semaglutide has been extensively studied, with the SELECT trial (semaglutide 2.4mg in obesity with established cardiovascular disease) and SUSTAIN-6 trial (semaglutide 1.0mg in type 2 diabetes) demonstrating cardiovascular safety
As with anything, too much of a good thing is possible, she says
With few exceptions, recent meta-analyses report that GLP-1 receptor therapies do not increase cancer incidence and may lower risk in some cases
In 2008 alone, prescription painkillers (including benzodiazepines) were involved in 14,800 overdose deaths, more than heroin and cocaine combined
Highly efficient retinal metabolism in cones
Your healthcare provider will determine the right dosage and form for you based on your specific needs and health condition